Evaluation of systemic inflammatory response (SIR) markers in pancreatic ductal adenocarcinoma (PDAC)

被引：0

作者：

Markus, M. ^{[1
]}

Kasper, S. ^{[1
]}

Noureddine, R. ^{[1
]}

Abramczyk, M. ^{[1
]}

Paul, A. ^{[2
]}

Gerken, G. ^{[3
]}

Schmid, K. W. ^{[4
]}

Markus, P. ^{[5
]}

Schumacher, B. ^{[6
]}

Meiler, J. ^{[1
]}

Wiesweg, M. ^{[1
]}

Kaiser, G. ^{[2
]}

Dechene, A. ^{[3
]}

Trarbach, T. ^{[7
]}

Schuler, M. ^{[1
]}

Abendroth, A. ^{[1
]}

机构：

[1] Univ Klinikum Essen, Westdeutsch Tumorzentrum, Innere Klin Tumorforsch, Essen, Germany

[2] Univ Klinikum Essen, Westdeutsch Tumorzentrum, Klin Allgemein Viszeral & Transplantat Chirurg, Essen, Germany

[3] Univ Klinikum Essen, Westdeutsch Tumorzentrum, Klin Gastroenterol & Hepatol, Essen, Germany

[4] Univ Klinikum Essen, Westdeutsch Tumorzentrum, Inst Pathol, Essen, Germany

[5] Elisabeth Krankenhaus Essen, Klin Allgemein Viszeral & Unfallchirurg, Essen, Germany

[6] Elisabeth Krankenhaus Essen, Klin Gastroenterol, Essen, Germany

[7] iOMEDICO AG, Freiburg, Germany

来源：

Oncology Research and Treatment | 2015年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V25

引用

页码：4 / 5

页数：2

共 50 条

[1] Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
Salmiheimo, Aino
Mustonen, Harri
Stenman, Ulf-Hakan
Puolakkainen, Pauli
Kemppainen, Esko
Seppanen, Hanna
Haglund, Caj
PLOS ONE, 2016, 11 (09):
[2] Oral cavity immune response in pancreatic ductal adenocarcinoma (PDAC)
Marquez, J. P.
Lucero-Diaz, P. A.
Matute-Briseno, J. A.
Rosas-Delgado, M. O.
Camacho-Hernandez, A.
Cortez-Vargas, Y.
Nava-Sanchez, I.
Montano, G. T.
Montijo-Fernandez, L. N.
Perez-Astorga, M. A.
ANNALS OF ONCOLOGY, 2018, 29 : 44 - 44
[3] Targeting Pancreatic Ductal Adenocarcinoma (PDAC)
Parrasia, Sofia
Zoratti, Mario
Szabo, Ildiko
Biasutto, Lucia
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2021, 55 (01) : 61 - 90
[4] Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC).
Fountzilas, Christos
Wilkinson, Grey A.
Eng, Kevin H.
Fields, Paul
Arora, Sukeshi Patel
Kalinski, Pawel
Raber, Patrick
Nuovo, Gerard
Coffey, Matthew C.
Mahalingam, Devalingam
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
Le, Kai
Wang, Jia
Zhang, Tao
Guo, Yifan
Chang, Hong
Wang, Siyuan
Zhu, Bin
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (04): : 422 - 427
[6] Pancreatic ductal adenocarcinoma (PDAC) early detection
Hinestrosa, Juan P.
Dhani, Harmeet
Schroeder, Gregor
Lewis, Jean M.
Balcer, Heath I.
Kurzrock, Razelle
Keith, Dove
Sears, Rosalie
Billings, Paul
CANCER RESEARCH, 2023, 83 (07)
[7] Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
Chandana, Sreenivasa
Babiker, Hani M.
Mahadevan, Daruka
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (02) : 161 - 177
[8] Inflammatory Processes: Key Mediators of Oncogenesis and Progression in Pancreatic Ductal Adenocarcinoma (PDAC)
Yang, Liu
Qiao, Shuangying
Zhang, Ge
Lu, Aiping
Li, Fangfei
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (20)
[9] Circulating tumour DNA methylation are markers for early detection of pancreatic ductal adenocarcinoma (PDAC)
Liu, X.
He, Q.
Liang, Z.
Wu, H.
Li, Y.
Zhang, Z.
Yu, L.
Dai, M.
Guo, S.
Jin, G.
Shen, S.
Su, Z.
Ma, C.
Xie, Z.
Liu, R.
ANNALS OF ONCOLOGY, 2020, 31 : S1289 - S1289
[10] Circulating tumor DNA methylation as markers for early detection of pancreatic ductal adenocarcinoma (PDAC).
Liu Xiaoding
Guo Shiwei
Ma Chengcheng
Li Yatong
Liu Xiaoqian
Zhang Zhiwen
Yu Lianyuan
Dai Menghua
Shen Shuo
Wu, Huanwen M.
Su Zhixi
He Qiye
Liu Rui
Gang Jin
Liang Zhiyong
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

← 1 2 3 4 5 →